Skip to main content
Clinical Trials/NCT05459142
NCT05459142
Completed
Not Applicable

Safety and Acceptability of Telemedicine Medical Abortion Service Using the "No-test" Protocol in Azerbaijan.

Gynuity Health Projects1 site in 1 country50 target enrollmentJune 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pregnancy Related
Sponsor
Gynuity Health Projects
Enrollment
50
Locations
1
Primary Endpoint
The incidence rate of adverse events resulting from the remote provision of medical abortion
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this study is to pilot and evaluate a telemedicine medical abortion service delivery that allows remote communication between the woman and provider and limits medically unnecessary in-person visits to health or diagnostic centers.

Detailed Description

The goal of this study is to pilot and evaluate a telemedicine medical abortion (TMA) service delivery that allows remote communication between the woman and provider and limits medically unnecessary in-person visits to health or diagnostic centers. Providers will provide counseling by phone or video about pregnancy options and give detailed information about the medical abortion process, expected side effects, and where to seek additional care. The provider will then evaluate the woman's eligibility for TMA service by following the no-test protocol and discuss at-home follow-up using a symptom checklist and a high-sensitivity urine pregnancy test. If pre-treatment tests are needed, women will be referred to a nearby diagnostic center and test results will be forwarded to the study provider. Participants will receive medications by mail or courier service or pick them up at the pharmacy or study clinics, take medications as instructed, and complete at-home follow-ups as discussed with the provider.

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
November 30, 2022
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Is pregnant as determined by a pregnancy test or ultrasound (if obtained prior to contacting the study site)
  • Has no contraindications to medical abortion
  • Has access to a phone
  • Is able to take mifepristone on or before 63 days of gestation

Exclusion Criteria

  • Medically ineligible for medical abortion
  • Gestational age above 63 days based on LMP

Outcomes

Primary Outcomes

The incidence rate of adverse events resulting from the remote provision of medical abortion

Time Frame: 6 weeks

Adverse events such as regimen non-compliance or medically unnecessary interventions associated with remote provision of medical abortion.

Secondary Outcomes

  • Satisfaction with remote provision of medical abortion(6-weeks)

Study Sites (1)

Loading locations...

Similar Trials